Luiza L. Bagno

Luiza L. Bagno

Auto-generated profile, based on publicly available information

Luiza L. Bagno

University of Miami Miller School of Medicine, Miami, FL, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2021 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
LBLuiza L. Bagno
Luiza L. Bagno
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
WBWayne Balkan
Wayne Balkan
JHJoshua M. Hare
Joshua M. Hare
Mesenchymal stromal cells (MSCs; AKA mesenchymal stem cells) stimulate healing and reduce inflammation. Promising therapeutic responses are seen in many late-phase clinical trials, but others have ...

19 January 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ARAngela C. Rieger
Angela C. Rieger
LBLuiza L. Bagno
Luiza L. Bagno
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
VFVictoria Florea
Victoria Florea
JRJose Rodriguez
Jose Rodriguez
JHJoshua M. Hare
Joshua M. Hare
Therapies for heart failure with preserved ejection fraction (HFpEF) are lacking. Growth hormone-releasing hormone agonists (GHRH-As) have salutary effects in ischemic and nonischemic heart failure animal models. Accordingly, we hypothesized that GHRH-A treatment ameliorates chronic kidney disease (CKD)-induced HFpEF in a large-animal model. Female Yorkshire pigs (n = 16) underwent 5/6 nephrectomy via renal artery embolization and 12 wk later were randomized to receive daily subcutaneous injections of GHRH-A (MR-409; n = 8; 30 µg/kg) or placebo (n = 8) for 4 to 6 wk. Renal and cardiac structure and function were serially assessed postembolization. Animals with 5/6 nephrectomy exhibited CKD (elevated blood urea nitrogen [BUN] and creatinine) and faithfully recapitulated the hemodynamic features of HFpEF. HFpEF was demonstrated at 12 wk by maintenance of ejection fraction associated with increased left ventricular mass, relative wall thickness, end-diastolic pressure (EDP), end-diastolic pressure/end-diastolic volume (EDP/EDV) ratio, and tau, the time constant of isovolumic diastolic relaxation. After 4 to 6 wk of treatment, the GHRH-A group exhibited normalization of EDP (P = 0.03), reduced EDP/EDV ratio (P = 0.018), and a reduction in myocardial pro-brain natriuretic peptide protein abundance. GHRH-A increased cardiomyocyte [Ca2+] transient amplitude (P = 0.009). Improvement of the diastolic function was also evidenced by increased abundance of titin isoforms and their ratio (P = 0.0022). GHRH-A exerted a beneficial effect on diastolic function in a CKD large-animal model as demonstrated by improving hemodynamic, structural, and molecular characteristics of HFpEF. These findings have important therapeutic implications for the HFpEF syndrome. Significance This randomized, blinded study used rigorous hemodynamic tools to test the efficacy of a synthetic growth hormone-releasing hormone agonist (GHRH‐A) on the restoration of diastolic function in a large animal model of chronic kidney disease (CKD)-induced heart failure with preserved ejection fraction (HFpEF). CKD was produced in Yorkshire swine by performing a 5/6 nephrectomy via catheter-based renal artery embolization. HFpEF was evident at 12 wk postembolization. Daily injection of GHRH-A improved cardiac diastolic hemodynamics, including end-diastolic pressure, end-diastolic pressure–volume ratio, and stroke work, compared to placebo. Development of this swine model and therapeutic approach has important implications because of the high prevalence of CKD-induced HFpEF and cardiorenal syndromes, lack of effective therapies, and few large-animal models available for investigation.

2 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAngela C. Rieger
Angela C. Rieger
LBLuiza L Bagno
Luiza L Bagno
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
VFVictoria Florea
Victoria Florea
JRJose Rodriguez
Jose Rodriguez
JHJoshua M. Hare
Joshua M. Hare
Background: Therapies that improve morbidity and mortality in heart failure with preserved ejection fraction (HFpEF) are lacking. Growth hormone releasing hormone analogues (GHRH-A) reverse fibrosis and improve cardiac function in ischemic and non-ischemic animal models. We tested the hypothesis that GHRH-A treatment ameliorates chronic kidney disease (CKD)-induced HFpEF in a large animal model. Methods: Female Yorkshire pigs (n=16) underwent 5/6 nephrectomy via renal artery embolization, which induced HFpEF, and 12-weeks later received daily subcutaneous injections of GHRH-A (n=8) or placebo (n=8). Kidney function, renal and cardiac MRI, pressure-volume loops, and electrical stimulation were assessed at baseline, 12-weeks, and 16-18 weeks post-embolization. Results: The CKD model was confirmed by increased creatinine and BUN. HFpEF was demonstrated at 12 weeks by maintenance of ejection fraction associated with increased left ventricular mass, relative wall thickening, end-diastolic pressure (EDP), end-diastolic pressure-volume relationship (EDPVR), and tau. After 6 weeks of treatment, diastolic function improved in the GHRH-A group, evidenced by normalization of EDP (p=0.03) associated with improved diastolic compliance as measured by EDP/EDV ratio (p=0.018). Conclusion: A beneficial effect of GHRH-A in diastolic function was observed in a CKD large animal model that manifests the characteristics of HFpEF. These findings have important therapeutic implications for the HFpEF syndrome.

6 September 2018
Verified
Book Chapter
Closed access
VFVictoria Florea
Victoria Florea
MBMonisha N. Banerjee
Monisha N. Banerjee
LBLuiza Bagno
Luiza Bagno
ARAngela C. Rieger
Angela C. Rieger
WBWayne Balkan
Wayne Balkan
JHJoshua M. Hare
Joshua M. Hare

21 January 2019
Verified
Book Chapter
Closed access
ARAngela C. Rieger
Angela C. Rieger
LBLuiza Bagno
Luiza Bagno
VFVictoria Florea
Victoria Florea
ISIvonne H. Schulman
Ivonne H. Schulman